A Study to Evaluate Safety, Tolerability, and Bioavailability of Subcutaneous Lirentelimab (AK002) in Adult Healthy Volunteers

A Phase 1 Study to Evaluate Safety, Tolerability, and Bioavailability of Subcutaneously Administered Lirentelimab (AK002) in Adult Healthy Volunteers

This is a Phase 1, single-center study to evaluate safety, tolerability, and bioavailability of subcutaneously administered lirentelimab (AK002) in adult healthy volunteers. Subjects will receive a single dose of intravenous AK002 or subcutaneous lirentelimab (AK002) assigned in a double-blind, randomized fashion.

Study Overview

• Status: Completed
• Conditions: Study Conducted in Healthy Volunteers
• Intervention / Treatment: Other: Placebo; Drug: lirentelimab (AK002)

• Study Type: Interventional
• Enrollment (Actual): 66
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • Florida
    • Edgewater, Florida, United States, 32132
      • Allakos Investigational Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

1. Provided written informed consent.
2. Male or female aged ≥18 and ≤65 years at the time of signing the ICF.
3. Determined by the Investigator to be in good health as documented by medical history, vital signs, physical examination, laboratory assessments, ECG, and by general observations.
4. Subjects must weigh at least 50 kg and have a BMI between 18 g/m2 and 30 kg/m2, inclusive.
5. Negative urine drug screen at Screening.
6. Subjects must have the ability and willingness to attend the necessary visits to the study center and the ability to communicate effectively with the study site personnel.
7. Negative screening ova and parasite test.
8. Female subjects must be either post-menopausal for at least 1 year with FSH level >40 IU/mL at Screening or surgically sterile (tubal ligation, hysterectomy, or bilateral oophorectomy) for at least 3 months, or if of childbearing potential, have a negative pregnancy test and agree to use dual methods of contraception, or abstain from sexual activity from Screening until the end of the study, or for 120 days following the last dose of study drug, whichever is longer.
9. Male subjects with female partners of childbearing potential must agree to use a highly effective method of contraception from Screening until the end of the study or for 120 days following the last dose of study drug, whichever is longer. All fertile men with female partners of childbearing potential should be instructed to contact the Investigator immediately if they suspect their partner might be pregnant (e.g., missed or late menstrual period) at any time during study participation.

Exclusion Criteria:

1. Peripheral blood absolute eosinophil count >300/µL.
2. Known hypersensitivity to any constituent of the study drug.
3. Women who are pregnant, breastfeeding, or planning to become pregnant while participating in the study.
4. Presence of abnormal laboratory values considered to be clinically significant by the Investigator.
5. Any disease of condition (medical or surgical) which, in the opinion of the Investigator, would place the subject at increased risk.
6. History of malignancy except carcinoma in situ in the cervix, early stage prostate cancer, or non-melanoma skin cancers.
7. Treatment with chemotherapy or radiotherapy in the preceding 6 months.
8. Treatment for a helminthic parasitic infection within 6 months of screening.
9. Use during the 30 days before Screening (or 5 half-lives, whichever is longer) or use during the Screening period of omalizumab, dupilumab, systemic immunosuppressive drugs, or systemic corticosteroids, except if receiving as part of a premedication protocol.
10. Vaccination with live attenuated vaccines within 30 days prior to initiation of treatment in the study, during the treatment period, or vaccination expected within 5 half-lives (4 months) of study drug administration.
11. Positive hepatitis serology results, except for vaccinated subjects or subjects with past but resolved hepatitis, at Screening.
12. Positive HIV serology results at Screening.
13. Alcohol, drug, or other substance abuse or dependence.
14. Any other reason that, in the opinion of the Investigator or Medical Monitor, makes the subject unsuitable for enrollment.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Sequential Assignment
• Masking: Quadruple

Number of Arms

10

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Placebo	Other: Placebo; Placebo
Experimental: SC 0.3 mg/kg of lirentelimab (AK002); Subjects in this arm will receive a single dose of 0.3 mg/kg of lirentelimab (AK002) administered subcutaneously.	Drug: lirentelimab (AK002); Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8.
Experimental: SC 1 mg/kg of lirentelimab (AK002); Subjects in this arm will receive a single dose of 1 mg/kg of lirentelimab (AK002) administered subcutaneously.	Drug: lirentelimab (AK002); Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8.
Experimental: SC 3 mg/kg of lirentelimab (AK002); Subjects in this arm will receive a single dose of 3 mg/kg of lirentelimab (AK002) administered subcutaneously.	Drug: lirentelimab (AK002); Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8.
Experimental: SC 5 mg/kg of lirentelimab (AK002); Subjects in this arm will receive a single dose of 5 mg/kg of lirentelimab (AK002) administered subcutaneously.	Drug: lirentelimab (AK002); Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8.
Experimental: IV 1 mg/kg of lirentelimab (AK002); Subjects in this arm will receive a single dose of 1 mg/kg of lirentelimab (AK002) administered intravenously.	Drug: lirentelimab (AK002); Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8.
Experimental: IV 3 mg/kg of lirentelimab (AK002); Subjects in this arm will receive a single dose of 3 mg/kg of lirentelimab (AK002) administered intravenously.	Drug: lirentelimab (AK002); Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8.
Experimental: IV 3 mg/kg of lirentelimab (AK002) (Priming); Subjects in this arm will receive a single dose of 3 mg/kg of lirentelimab (AK002) administered intravenously from an IV bag prepared with extra volume for priming IV set.	Drug: lirentelimab (AK002); Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8.
Experimental: SC 300 mg of lirentelimab (AK002); Subjects in this arm will receive a single dose of 300 mg of lirentelimab (AK002) administered subcutaneously.	Drug: lirentelimab (AK002); Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8.
Experimental: SC 450 mg of lirentelimab (AK002); Subjects in this arm will receive a total of 450 mg of lirentelimab (AK002), administered as two separate subcutaneous injections.	Drug: lirentelimab (AK002); Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Safety and tolerability of lirentelimab (AK002) administered subcutaneously by evaluating adverse events assessed using the CTCAE version 5	Day 0 (baseline) to Day 85
Pharmacokinetics, including bioavailability, of lirentelimab (AK002) administered subcutaneously	Day 0 (baseline) to Day 85

Secondary Outcome Measures

Outcome Measure	Time Frame
Pharmacodynamics of lirentelimab (AK002) SC formulation as measured by changes in absolute peripheral blood counts of esoinophils	Day 0 (baseline) to Day 85
Bioavailability of lirentelimab (AK002) SC formulation relative to lirentelimab (AK002) IV by analyzing the area under the serum AUC	Day 0 (baseline) to Day 85

Collaborators and Investigators

• Sponsor: Allakos Inc.
• Investigators: Study Director: Henrik Rasmussen, MD, PhD, Allakos Inc.

Study record dates

Study Major Dates

• Study Start (Actual): March 23, 2020
• Primary Completion (Actual): February 10, 2021
• Study Completion (Actual): February 10, 2021

Study Registration Dates

• First Submitted: March 24, 2020
• First Submitted That Met QC Criteria: March 25, 2020
• First Posted (Actual): March 27, 2020

Study Record Updates

• Last Update Posted (Actual): April 18, 2023
• Last Update Submitted That Met QC Criteria: April 17, 2023
• Last Verified: April 1, 2023

More Information

Terms related to this study

• Other Study ID Numbers: AK002-017

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No